<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124366</url>
  </required_header>
  <id_info>
    <org_study_id>0005</org_study_id>
    <nct_id>NCT05124366</nct_id>
  </id_info>
  <brief_title>Propolis Extract, Nanovitamin C and Nanovitamin E on Desquamative Gingivitis</brief_title>
  <official_title>Propolis Extract, Nanovitamin C and Nanovitamin E on Desquamative Gingivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Complutense de Madrid</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To evaluate the effectiveness of a gel containing nanovitamin C, nanovitamin E and&#xD;
      propolis extract compared to a placebo in the treatment of desquamative gingivitis (GD) in&#xD;
      patients with mucocutaneous diseases with gingival involvement. The possible improvement in&#xD;
      the quality of life of these patients after treatment will also be evaluated.&#xD;
&#xD;
      Study design: Double-blind, randomized controlled study.&#xD;
&#xD;
      Patients: GD patients are being selected from the Postgraduate 'Specialist in Oral Medicine'&#xD;
      of the Faculty of Dentistry, Complutense University of Madrid.&#xD;
&#xD;
      Allocation: Patients are being randomly assigned to the study group (dental prophylaxis +&#xD;
      oral hygiene instructions + use of propolis gel for 4 weeks) or to the placebo group (dental&#xD;
      prophylaxis + oral hygiene instructions + use of placebo gel for 4 weeks ). Both the study&#xD;
      gel and the placebo are being used for brushing their teeth and for application in areas with&#xD;
      GD.&#xD;
&#xD;
      Variables: The severity of the GD will be collected according to the scale of Arduino et al.&#xD;
      2017 and the periodontal variables (plaque index, probing bleeding index and probing depth).&#xD;
      Pain during treatment will be recorded using a 10 cm visual analog scale (VAS). The quality&#xD;
      of life in relation to oral health will be recorded using the Oral Health Impact Profile-14&#xD;
      (OHIP-14) questionnaire. These variables will be collected on day 0, 2 and 4 weeks after&#xD;
      using the study gel or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Actual">October 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The severity of the GD will be collected according to the scale of Arduino et al. 2017</measure>
    <time_frame>Baseline</time_frame>
    <description>The Scale collects a value for each sextant in vestibular and another value in lingual / palatal (12 in total, six times vestibular and six times lingual / palatal). The criteria for scoring are as follows: (0) no detectable gingival lesions present, (1) only white lesions, (2) mild erythema (&lt;3mm from the gingival margins), (3) one or more blisters or erythema clinically obvious (&gt; 3mm from the gingival margins), (4) erosion or ulcer. When there are different characteristics, the clinician should choose the highest index, so the total score can vary from 0 to 48. Higher results indicate a more serious clinical disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The severity of the GD will be collected according to the scale of Arduino et al. 2017</measure>
    <time_frame>2 weeks</time_frame>
    <description>The Scale collects a value for each sextant in vestibular and another value in lingual / palatal (12 in total, six times vestibular and six times lingual / palatal). The criteria for scoring are as follows: (0) no detectable gingival lesions present, (1) only white lesions, (2) mild erythema (&lt;3mm from the gingival margins), (3) one or more blisters or erythema clinically obvious (&gt; 3mm from the gingival margins), (4) erosion or ulcer. When there are different characteristics, the clinician should choose the highest index, so the total score can vary from 0 to 48. Higher results indicate a more serious clinical disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The severity of the GD will be collected according to the scale of Arduino et al. 2017</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Scale collects a value for each sextant in vestibular and another value in lingual / palatal (12 in total, six times vestibular and six times lingual / palatal). The criteria for scoring are as follows: (0) no detectable gingival lesions present, (1) only white lesions, (2) mild erythema (&lt;3mm from the gingival margins), (3) one or more blisters or erythema clinically obvious (&gt; 3mm from the gingival margins), (4) erosion or ulcer. When there are different characteristics, the clinician should choose the highest index, so the total score can vary from 0 to 48. Higher results indicate a more serious clinical disease.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Desquamative Gingivitis</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nanovitamin E, nanovitamin C and propolis extract gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gel without nanovitamin E, nanovitamin C and propolis extract</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dental prophylaxis + oral hygiene instructions</intervention_name>
    <description>Follow up: 2 weeks and 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients over 18 years of age.&#xD;
&#xD;
          2. Patients with a clinical and histological diagnosis of some mucocutaneous disease.&#xD;
             Patients diagnosed with oral lichen planus will be selected according to the American&#xD;
             Academy of Oral and Maxillofacial Pathology, pemphigus vulgaris and / or scarring&#xD;
             pemphigoid according to the 2015 World Workshop on Oral Medicine.&#xD;
&#xD;
          3. Patients who present GD, that is, erythema, epithelial desquamation, atrophy, painful&#xD;
             erosions or ulceration of the free and / or attached gingiva, which is not related to&#xD;
             the local accumulation of plaque.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Being in cancer treatment with head and neck radiotherapy, chemotherapy or&#xD;
             immunotherapy.&#xD;
&#xD;
          2. Being diabetic.&#xD;
&#xD;
          3. Being on topical corticosteroid treatment in the previous 4 weeks or systemic&#xD;
             treatment in the previous 8 weeks.&#xD;
&#xD;
          4. Those patients who do not present the anterosuperior sector (from canine to upper&#xD;
             canine) or the anteroinferior sector (from canine to lower canine) will also be&#xD;
             excluded.&#xD;
&#xD;
          5. Pregnant or breastfeeding.&#xD;
&#xD;
          6. Being a smoker.&#xD;
&#xD;
          7. Use of rinses for plaque control.&#xD;
&#xD;
          8. Being medicated with drugs associated with gingival enlargement such as cyclosporine,&#xD;
             calcium channel blockers and phenytoin.&#xD;
&#xD;
          9. To have taken antibiotics and / or anti-inflammatories 3 months before the study.&#xD;
&#xD;
         10. Taking medications capable of producing lichenoid reactions.&#xD;
&#xD;
         11. Patients who do not want to sign the informed consent.&#xD;
&#xD;
         12. Patients with periodontitis according to the consensus criteria of Papapanou et al.&#xD;
             2018 or patients treated for unstable periodontal disease according to the&#xD;
             classification of Chapple et al. 2017.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universidad Complutense de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa María López-Pintor, PhD</last_name>
      <phone>0034913942013</phone>
      <email>rmlopezp@ucm.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Complutense de Madrid</investigator_affiliation>
    <investigator_full_name>Rosa María López-Pintor Muñoz</investigator_full_name>
    <investigator_title>Dos, PhD, Associate Professor.</investigator_title>
  </responsible_party>
  <keyword>desquamative gingivitis</keyword>
  <keyword>lichen planus</keyword>
  <keyword>propolis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gingivitis</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We will try to publish it as a scientific article</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

